CGON - NASDAQ
CG Oncology, Inc. Common stock
$54.42
-0.85%CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
At a Glance
Live SnapshotCG Oncology, Inc. Common stock Management Team
Mr. Arthur Kuan
Chairman & Chief Executive Officer
Compensation
$1,037,565
Ms. Corleen M. Roche
Chief Financial Officer
Compensation
$687,827
Dr. Vijay Kasturi M.D.
Chief Medical Officer
Compensation
$299,688
Mr. Swapnil Bhargava Ph.D.
Chief Technical Officer
Mr. Joshua F. Patterson
General Counsel, Chief Compliance Officer & Secretary
Mr. Robert Lapetina
Interim Principal Financial & Accounting Officer
Mr. Ambaw Bellete M.S.
President & Chief Operating Officer
Compensation
$769,967
Ms. Sarah Connors
Vice President of Communications & Patient Advocacy
Mr. Bing Kung
Vice President of Corporate Development
Ms. Amy Steele
Vice President of Finance, Accounting & Administration
CG Oncology, Inc. Common stock Insider Positioning
During the last 12 months, insiders have purchased $50.00M and sold $3.41M worth of CGON shares, resulting in $46.59M of net buying activity.
3 Months
0
0.00
16.9K
1.22M
-1.2M
-$1.22M
3-6 Months
0
0.00
654
28.88K
-29K
-$29K
6-9 Months
1.5M
50.00M
49.3K
1.96M
+48.0M
+$48.04M
9-12 Months
0
0.00
6.2K
190.31K
-190K
-$190K
Top Buyers
Liu Brian Guan-Chyun
Director
$50.00M
Top Sellers
Mulay James
Director
$3.00M
Post Leonard E
Director
$404K
Song Hong Fang
Director
$3K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $46.59M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
CGON - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | April 23, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 05, 2025 | 2025 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.